Literature DB >> 16574246

Elevation of IL-12 p40 and its antibody in myasthenia gravis with thymoma.

Hiroaki Yoshikawa1, Katsuaki Sato, Shigeki Edahiro, Yutaka Furukawa, Takahiro Maruta, Kazuo Iwasa, Hideto Watanabe, Shizuka Takaoka, Yasuhiro Suzuki, Masaharu Takamori, Masahito Yamada.   

Abstract

We examined the serum levels of cytokines, interferon (IFN)-alpha, IFN-gamma, interleukin (IL)-4, IL-12 p40, and IL-12 p70; those that affect the T helper 1 and 2 balance in patients with myasthenia gravis (MG). Among the cytokines tested, only IL-12 p40, together with the serum titer of anti-IL-12 p40 antibody, was significantly elevated in MG with thymoma. Their elevation was independent of the histopathology of thymoma. Thymectomy decreased the levels of IL-12 p40 accompanied by the anti-acetylcholine receptor antibody, but not anti-IL-12 p40 antibodies. These data strongly suggest the association of IL-12 p40 and its autoantibody with the immunopathology of MG with thymoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16574246     DOI: 10.1016/j.jneuroim.2006.02.012

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  3 in total

1.  Refractory Mycobacterium genavense infection secondary to thymoma-associated endogenous IL-12 inhibitor.

Authors:  Jessie Chen; MaiAnh Nguyen; Elaine Cheong; D Sean Riminton; Stephen Reddel
Journal:  BMJ Neurol Open       Date:  2022-05-18

2.  Identification of serum biomarkers for aging and anabolic response.

Authors:  Camellia Banerjee; Jagadish Ulloor; Edgar L Dillon; Qusai Dahodwala; Brittani Franklin; Thomas Storer; Paola Sebastiani; Melinda Sheffield-Moore; Randall J Urban; Shalender Bhasin; Monty Montano
Journal:  Immun Ageing       Date:  2011-06-20       Impact factor: 6.400

3.  Two-step nationwide epidemiological survey of myasthenia gravis in Japan 2018.

Authors:  Hiroaki Yoshikawa; Yumi Adachi; Yosikazu Nakamura; Nagato Kuriyama; Hiroyuki Murai; Yoshiko Nomura; Yasunari Sakai; Kazuo Iwasa; Yutaka Furukawa; Satoshi Kuwabara; Makoto Matsui
Journal:  PLoS One       Date:  2022-09-21       Impact factor: 3.752

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.